[Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
作者信息
Jiang W R, Fang L P, Chang N, Zhang J
出版信息
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
Abstract
摘要
相似文献
1
[Immuno-checkpoint inhibitor resistance and strategy in lung cancer].[肺癌中的免疫检查点抑制剂耐药性及策略]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
2
KEYNOTE-024: Unlocking a pathway to lung cancer cure?KEYNOTE-024：开启肺癌治愈之路？
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
3
There and back again: An immunotherapy tale.往返之间：一个免疫疗法的故事。
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
4
Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.程序性死亡-1抑制对非小细胞肺癌的临床益处与较高的血液嗜酸性粒细胞水平相关。
Acta Oncol. 2020 Mar;59(3):257-259. doi: 10.1080/0284186X.2019.1695063. Epub 2019 Nov 22.
5
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.中国肺癌的回顾与展望：免疫检查点抑制剂的临床进展。
Oncologist. 2019 Feb;24(Suppl 1):S21-S30. doi: 10.1634/theoncologist.2019-IO-S1-s02.
6
[Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].[非小细胞肺癌中免疫检查点抑制剂的预测生物标志物]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 12;43(2):87-91. doi: 10.3760/cma.j.issn.1001-0939.2020.02.004.
7
Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.在鳞状细胞非小细胞肺癌中使用抗PD-L1药物克服对PD-1抑制剂的原发性耐药：病例报告
Clin Lung Cancer. 2020 Mar;21(2):e45-e48. doi: 10.1016/j.cllc.2019.11.011. Epub 2019 Nov 20.
8
Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.最终，经过数十年，免疫检查点抑制剂取代了小细胞肺癌的治疗标准。
Immunotherapy. 2019 Apr;11(6):457-460. doi: 10.2217/imt-2019-0010.
9
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.PD-1/PD-L1 抑制剂联合胸部放疗治疗转移性肺癌患者的临床结局。
JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808.
10
Role of immune-checkpoint inhibitors in lung cancer.免疫检查点抑制剂在肺癌中的作用。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075.
Zotero 插件